• Psyence Group (PSYG) has provided an update on its  three strategic focus areas
  • Dr. Clive Ward-Able has been appointed as Medical Director, Head of Research & Development and Early Commercialization
  • ISO22000 certified commercial psilocybin production facility and lab upgraded
  • GOODMIND™, functional mushroom product, launched online and in-store
  • The company completed a C$1.273 million private placement

Psyence Group (PSYG) has provided an update on its  three strategic focus areas namely: Psyence Therapeutics, Psyence Production and Psyence Function.

Highlights:

  • Partnership with CRO Clerkenwell Health to design and deliver Psyence’s UK clinical trial progressing; exclusive licensing agreement with Filament Health
  • Dr. Clive Ward-Able has been appointed as Medical Director, Head of Research & Development and Early Commercialization for Psyence
  • ISO22000 certified commercial psilocybin production facility and lab upgraded
  • Received an import permit from Health Canada on behalf of Psilo Scientific
  • GOODMIND™, functional mushroom product, launched online and in-store, sale through 300 stores of one of Africa’s largest coffee retail chains
  • Previously announced C$1.273 million private placement being closed
  • Exploring capital market initiatives in UK, hires Investment Bank

Psyence CEO Dr. Neil Maresky, sat down with Coreena Robertson to discuss the update.

Psyence is a life science biotechnology company focused on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

Psysence Group Inc. (PSYG) opened trading at C$0.085 per share.

More From The Market Online
stock market down

@ the Bell: TSX sinks as producer prices rise

The TSX couldn’t get a rally going on Tuesday after reports that the Industrial Product Price Index rose 1.5 per cent in April.

Voyageur Pharmaceuticals signs $2.6M contract in Latin America

Voyageur Pharmaceuticals (TSXV:VM) announces its first international distribution agreement with a C$2.6 million commitment.

Red Light Holland and PharmAla notch psilocybin extraction

Red Light Holland (CSE:TRIP) reveals it has successfully completed the first phase of psilocybin extraction to PharmAla Biotech (CSE:MDMA).

@ the Bell: TSX rises during Wall Street’s holiday

Canada's main stock index advanced on Monday, supported by higher commodity prices, while investors await inflation data.